Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499491 | 0.83 | KCNQ3 (0.49) | MEN1KMT2AMAPTCASP3SENP7 | |
| SCHEMBL991621 | 0.83 | KCNQ3 (0.49) | MEN1KMT2AMAPTCASP3SENP7 | |
| SCHEMBL15517335 | 0.83 | TAS1R3 (0.43) | MEN1KMT2AMAPTCASP3SENP7 | |
| SCHEMBL3170407 | 0.83 | CES2 (0.64) | MEN1KMT2AMAPTCASP3SENP7 | |
| SCHEMBL10399614 | 0.83 | SRD5A2 (0.53) | MEN1KMT2AMAPTCASP3SENP7 | |
| SCHEMBL4072517 | 0.81 | IDO1 (0.46) | MEN1KMT2AMAPTCASP3SENP7 | |
| SCHEMBL16956565 | 0.81 | TAS1R3 (0.45) | MEN1KMT2AMAPTCASP3SENP7 | |
| SCHEMBL30308290 | 0.81 | TSHR (0.65) | MAPTTSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL109599 | 0.81 | TSHR (0.65) | MAPTTSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL20084007 | 0.81 | KCNQ3 (0.47) | MEN1KMT2AMAPTCASP3SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493546-B1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731206-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-3954685-B1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | US HEALTH (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| US-12365653-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2025-07-22 | — | — | US | disclosed |
| CN-120058445-A | Method for generating aryl phenol compound by hydroxylation of uranium photocatalytic aryl fluorine compound and application of method | 华东师范大学 | 2025-05-30 | — | — | CN | disclosed |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250066345-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Cadrenal Therapeutics, Inc. | 2025-02-27 | — | — | US | disclosed |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | LILAC THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| EP-0735018-B1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL CO (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0922693-A1 | Process for the preparation of 3-chloro-4-fluorobenzoyl chloride | Clariant GmbH (DE) | 1999-06-16 | — | — | EP | disclosed |
| EP-0743938-B1 | SUBSTITUTED SPIRO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5739401-A | N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0628550-B1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | SANOFI SA (FR) | 1998-02-25 | — | — | EP | disclosed |
| EP-0743938-A1 | SUBSTITUTED SPIRO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-27 | — | — | EP | disclosed |
| EP-0735018-A1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
| WO-1995021817-A1 | SUBSTITUTED SPIRO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0628550-A2 | Pyridazines as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-14 | — | — | EP | disclosed |
| US-4743703-A | Herbicidal 4-fluoroalkyl-4'-nitrodiphenyl ethers | ROHM AND HAAS COMPANY (US) | 1988-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | MEN1 2497/4885KMT2A 822/4885MAPT 3217/4885 |
| US-12365653-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | LDHB, LDHA, PDHA1 | MEN1 2648/4885KMT2A 2190/4885MAPT 3719/4885 |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | MEN1 2497/4885KMT2A 822/4885MAPT 3217/4885 |
| US-20250066345-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | ALOX12, LOX, ALOX15 | MEN1 4500/4885KMT2A 3409/4885MAPT 3763/4885 |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | GLS, DUOX1, HAO1 | MEN1 2340/4885KMT2A 3008/4885MAPT 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.